GLP-1 agonists like Wegovy and Zepbound offer powerful weight loss-up to 21% of body weight-but come with nausea, cost barriers, and long-term use requirements. Learn how they work, who they’re for, and what to expect.
Elderly patients on diuretics face a high risk of dehydration and kidney injury. Learn how to prevent hospitalization with simple, evidence-backed strategies for fluid management, monitoring, and daily care.
The Federal Circuit Court holds exclusive authority over U.S. pharmaceutical patent cases, shaping how drugs are patented, challenged, and brought to market. Its rulings on ANDA litigation, dosing patents, and jurisdiction directly impact drug prices and generic access.
Generic drugs save money, but for kids and seniors, switching can cause confusion, refusal, or missed doses. Learn how to explain substitutions clearly, avoid common mistakes, and build trust with vulnerable patients.
ADHD in adults is more than forgetfulness-it’s a barrier to work, relationships, and self-confidence. With medication, coaching, and simple organization systems, many find lasting relief. Here’s how to build a safe, effective plan that actually works.
Osteoarthritis and rheumatoid arthritis are two very different conditions. One is wear and tear, the other is an autoimmune attack. Knowing which one you have changes everything about treatment.
Explaining vascular, frontotemporal, and Lewy body dementia: their causes, symptoms, diagnosis challenges, and why accurate identification is crucial for proper care.
The FDA issued over 60 drug safety alerts in 2025, including major updates on opioids, ADHD meds, and Alzheimer's treatments. Learn what changed, why it matters, and how to stay safe.
Environmental monitoring in manufacturing prevents contamination by testing surfaces, air, and water for microbes and toxins. Learn how zone-based sampling, ATP testing, and regulatory standards keep products safe and compliant.
Antitrust laws in the generic drug market prevent big pharma from blocking cheaper alternatives through pay-for-delay deals, sham petitions, and product hopping. These tactics cost consumers billions - and regulators are fighting back.